Related Experiment Video
Updated: Jan 22, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Do patients on biologic drugs for rheumatic disease need PCP prophylaxis?
Joy-Ann Tabanor1, Santhanam Lakshminarayanan2
1Fellow, Division of Rheumatology, University of Connecticut School of Medicine, Farmington, CT, USA. tabanor@uchc.edu.
No abstract available in PubMed .
More Related Videos
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
07:59Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
Published on: May 31, 2024
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...